Compare Stocks: RXRX, CRSP, TGTX, and SYRE

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRSP CRISPR Therapeutics	$50.10 -2.8%	$55.12	$44.12 ▼ $75.06	$4.98B	1.76	1.84 million shs	1.34 million shs
RXRX Recursion Pharmaceuticals	$3.84 -4.2%	$3.60	$2.77 ▼ $7.18	$2.15B	1.04	30.20 million shs	19.71 million shs
SYRE Spyre Therapeutics	$80.45 -6.3%	$93.47	$18.71 ▼ $110.18	$8.75B	3.1	1.59 million shs	1.44 million shs
TGTX TG Therapeutics	$54.34 -1.7%	$53.96	$26.76 ▼ $59.30	$8.46B	1.8	1.89 million shs	1.00 million shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRSP CRISPR Therapeutics	-3.45%	-10.10%	-0.33%	+2.16%	-29.45%
RXRX Recursion Pharmaceuticals	-8.03%	-16.11%	+25.31%	+20.06%	-24.62%
SYRE Spyre Therapeutics	+0.25%	-7.36%	-5.19%	-13.19%	+348.80%
TGTX TG Therapeutics	-0.18%	+2.52%	+2.56%	+0.69%	+63.71%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRSP CRISPR Therapeutics	$50.10 -2.8%	$55.12	$44.12 ▼ $75.06	$4.98B	1.76	1.84 million shs	1.34 million shs
RXRX Recursion Pharmaceuticals	$3.84 -4.2%	$3.60	$2.77 ▼ $7.18	$2.15B	1.04	30.20 million shs	19.71 million shs
SYRE Spyre Therapeutics	$80.45 -6.3%	$93.47	$18.71 ▼ $110.18	$8.75B	3.1	1.59 million shs	1.44 million shs
TGTX TG Therapeutics	$54.34 -1.7%	$53.96	$26.76 ▼ $59.30	$8.46B	1.8	1.89 million shs	1.00 million shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRSP CRISPR Therapeutics	-3.45%	-10.10%	-0.33%	+2.16%	-29.45%
RXRX Recursion Pharmaceuticals	-8.03%	-16.11%	+25.31%	+20.06%	-24.62%
SYRE Spyre Therapeutics	+0.25%	-7.36%	-5.19%	-13.19%	+348.80%
TGTX TG Therapeutics	-0.18%	+2.52%	+2.56%	+0.69%	+63.71%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CRSP CRISPR Therapeutics	2.68	Moderate Buy	$67.50	34.73% Upside
RXRX Recursion Pharmaceuticals	2.20	Hold	$8.06	109.90% Upside
SYRE Spyre Therapeutics	2.88	Moderate Buy	$110.40	37.23% Upside
TGTX TG Therapeutics	2.56	Moderate Buy	$63.00	15.94% Upside

Current Analyst Ratings Breakdown

Latest RXRX, CRSP, TGTX, and SYRE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/11/2026	SYRE Spyre Therapeutics	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Buy	$120.00
10/9/2026	CRSP CRISPR Therapeutics	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
10/9/2026	CRSP CRISPR Therapeutics	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
10/8/2026	TGTX TG Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Buy (B-) ➝ Buy (B)
10/6/2026	TGTX TG Therapeutics	Zacks Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Strong Sell ➝ Hold
10/1/2026	SYRE Spyre Therapeutics	BTIG Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$121.00
10/1/2026	SYRE Spyre Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Overweight	$110.00
9/28/2026	CRSP CRISPR Therapeutics	Citigroup Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Market Outperform
9/23/2026	CRSP CRISPR Therapeutics	William Blair Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Strong-Buy
9/21/2026	TGTX TG Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Hold (C+) ➝ Buy (B-)
9/9/2026	SYRE Spyre Therapeutics	Wedbush Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Outperform	$123.00

(Data available from 10/13/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CRSP CRISPR Therapeutics	$3.51M	1,380.11	N/A	N/A	$20.17 per share	2.48
RXRX Recursion Pharmaceuticals	$74.68M	27.53	N/A	N/A	$2.14 per share	1.79
SYRE Spyre Therapeutics	$890K	9,211.98	N/A	N/A	$7.21 per share	11.16
TGTX TG Therapeutics	$616.29M	13.50	$2.75 per share	19.73	$4.08 per share	13.32

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CRSP CRISPR Therapeutics	-$581.60M	-$4.76	N/A	N/A	N/A	-3,368.72%	-24.39%	-18.25%	11/9/2026 (Estimated)
RXRX Recursion Pharmaceuticals	-$644.76M	-$1.04	N/A	N/A	N/A	-945.94%	-50.41%	-38.25%	11/4/2026 (Estimated)
SYRE Spyre Therapeutics	-$155.20M	-$1.95	N/A	N/A	N/A	N/A	-30.74%	-22.23%	11/3/2026 (Estimated)
TGTX TG Therapeutics	$447.18M	$2.74	19.83	20.51	2.33	55.22%	73.49%	34.14%	11/2/2026 (Estimated)

Latest RXRX, CRSP, TGTX, and SYRE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/9/2026	Q3 2026	CRSP CRISPR Therapeutics	-$1.04	N/A	N/A	N/A	$14.62 million	N/A
11/4/2026	Q3 2026	RXRX Recursion Pharmaceuticals	-$0.2204	N/A	N/A	N/A	$12.98 million	N/A
11/3/2026	Q3 2026	SYRE Spyre Therapeutics	-$0.79	N/A	N/A	N/A	N/A	N/A
11/2/2026	Q3 2026	TGTX TG Therapeutics	$0.3588	N/A	N/A	N/A	$245.47 million	N/A
8/5/2026	Q2 2026	RXRX Recursion Pharmaceuticals	-$0.24	-$0.25	-$0.01	-$0.25	$10.97 million	$7.67 million
8/4/2026	Q2 2026	SYRE Spyre Therapeutics	-$0.7589	-$0.36	+$0.3989	-$0.36	N/A	N/A
8/3/2026	Q2 2026	CRSP CRISPR Therapeutics	-$1.19	-$0.94	+$0.25	-$0.94	$7.45 million	$10.18 million
8/3/2026	Q2 2026	TGTX TG Therapeutics	$0.3057	$0.05	-$0.2557	$0.05	$229.77 million	$240.34 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CRSP CRISPR Therapeutics	N/A	N/A	N/A	N/A	N/A
RXRX Recursion Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
SYRE Spyre Therapeutics	N/A	N/A	N/A	N/A	N/A
TGTX TG Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CRSP CRISPR Therapeutics	0.34	17.85	17.85
RXRX Recursion Pharmaceuticals	0.01	5.03	5.03
SYRE Spyre Therapeutics	N/A	18.53	18.53
TGTX TG Therapeutics	1.23	4.27	3.72

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CRSP CRISPR Therapeutics	69.20%
RXRX Recursion Pharmaceuticals	89.06%
SYRE Spyre Therapeutics	80.39%
TGTX TG Therapeutics	58.58%

Insider Ownership

Company	Insider Ownership
CRSP CRISPR Therapeutics	5.20%
RXRX Recursion Pharmaceuticals	6.65%
SYRE Spyre Therapeutics	15.69%
TGTX TG Therapeutics	8.87%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CRSP CRISPR Therapeutics	393	96.69 million	91.67 million	Optionable
RXRX Recursion Pharmaceuticals	600	535.34 million	499.74 million	Optionable
SYRE Spyre Therapeutics	112	101.91 million	85.92 million	Optionable
TGTX TG Therapeutics	399	153.07 million	139.49 million	Optionable

RXRX, CRSP, TGTX, and SYRE Headlines

Recent News About These Companies

TGTX Stock Rises 60% in 6 Months: Here's What You Should Know

October 13 at 11:51 AM | zacks.com

TG Therapeutics Announces Publication of Five-Year Comparative Analysis of BRIUMVI Versus Ocrelizumab and Ofatumumab in Relapsing Multiple Sclerosis

October 12 at 7:30 AM | businesswire.com

Tg Therapeutics, Inc. Announces Schedule of Data Presentations At Mstoronto2026

October 9, 2026 | marketscreener.comM

TG Therapeutics (TGTX) Stock May Be Undervalued Despite Fresh Newsflow

October 9, 2026 | finance.yahoo.com

TG Therapeutics (TGTX) Just Sparked A Bigger Question

October 8, 2026 | finance.yahoo.com

TG Therapeutics Announces Schedule of Data Presentations at MSToronto2026

October 8, 2026 | businesswire.com

TG Therapeutics (NASDAQ:TGTX) Stock Rating Raised to Hold at Zacks Research

October 8, 2026 | americanbankingnews.com

TG Therapeutics (NASDAQ:TGTX) Raised to Hold at Zacks Research

October 8, 2026 | marketbeat.com

TG Therapeutics (NASDAQ:TGTX) Stock Breaks Above 200-Day Moving Average - Here's What Happened

October 6, 2026 | americanbankingnews.com

TG Therapeutics (NASDAQ:TGTX) Shares Break Above 200 Day Moving Average - Should You Sell?

October 6, 2026 | marketbeat.com

Kuehn Law Encourages Investors of TG Therapeutics, Inc. to Contact Law Firm

September 28, 2026 | prnewswire.com

TG Therapeutics, Inc. (NASDAQ:TGTX) Receives Consensus Rating of "Hold" from Analysts

September 27, 2026 | marketbeat.com

TG Therapeutics Inc (TGTX)

September 24, 2026 | ru.investing.com

Dow Jones futures fall after Nasdaq hits new high; SanDisk, Micron trigger buy signals

September 23, 2026 | msn.com

Dow Jones futures: Nasdaq hits new high; SanDisk, Micron trigger buy signals

September 22, 2026 | msn.com

Bank of America Corp DE Acquires Shares of 1,309,788 TG Therapeutics, Inc. $TGTX

September 20, 2026 | marketbeat.com

Tidal Investments LLC Buys New Holdings in TG Therapeutics, Inc. $TGTX

September 19, 2026 | marketbeat.com

TG Therapeutics (TGTX) Could Be 19% Undervalued After Its Recent Rebound

September 18, 2026 | finance.yahoo.com

TG Therapeutics Eyes $1B Run Rate as BRIUMVI Gains MS Market Share

September 18, 2026 | marketbeat.com

TG Therapeutics (NASDAQ:TGTX) Trading 8.3% Higher - Here's Why

September 16, 2026 | marketbeat.com

TG Therapeutics (NASDAQ:TGTX) Director Sells 5,000 Shares

September 15, 2026 | insidertrades.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

RXRX, CRSP, TGTX, and SYRE Company Descriptions

CRISPR Therapeutics NASDAQ:CRSP

$50.10 -1.45 (-2.81%)

Closing price 04:00 PM Eastern

Extended Trading

$50.20 +0.10 (+0.20%)

As of 07:59 PM Eastern

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.

Recursion Pharmaceuticals NASDAQ:RXRX

$3.84 -0.17 (-4.24%)

Closing price 04:00 PM Eastern

Extended Trading

$3.85 +0.01 (+0.16%)

As of 07:59 PM Eastern

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

Spyre Therapeutics NASDAQ:SYRE

$80.45 -5.45 (-6.34%)

Closing price 04:00 PM Eastern

Extended Trading

$82.72 +2.27 (+2.83%)

As of 07:30 PM Eastern

Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004, a novel mechanism of action (MOA) mAb; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts.

TG Therapeutics NASDAQ:TGTX

$54.34 -0.93 (-1.68%)

Closing price 04:00 PM Eastern

Extended Trading

$54.28 -0.07 (-0.12%)

As of 07:30 PM Eastern

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest RXRX, CRSP, TGTX, and SYRE Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest RXRX, CRSP, TGTX, and SYRE Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

RXRX, CRSP, TGTX, and SYRE Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

RXRX, CRSP, TGTX, and SYRE Company Descriptions

CRISPR Therapeutics NASDAQ:CRSP

Recursion Pharmaceuticals NASDAQ:RXRX

Spyre Therapeutics NASDAQ:SYRE

TG Therapeutics NASDAQ:TGTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest RXRX, CRSP, TGTX, and SYRE Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest RXRX, CRSP, TGTX, and SYRE Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

RXRX, CRSP, TGTX, and SYRE Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

RXRX, CRSP, TGTX, and SYRE Company Descriptions

CRISPR Therapeutics NASDAQ:CRSP

Recursion Pharmaceuticals NASDAQ:RXRX

Spyre Therapeutics NASDAQ:SYRE

TG Therapeutics NASDAQ:TGTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools